DB:0TB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines.


Snowflake Analysis

Slightly overvalued with limited growth.

Share Price & News

How has Theravance Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 0TB's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.8%

0TB

0.6%

DE Pharmaceuticals

2.2%

DE Market


1 Year Return

55.9%

0TB

18.1%

DE Pharmaceuticals

-3.9%

DE Market

Return vs Industry: 0TB exceeded the German Pharmaceuticals industry which returned 18.8% over the past year.

Return vs Market: 0TB exceeded the German Market which returned -4.6% over the past year.


Shareholder returns

0TBIndustryMarket
7 Day-0.8%0.6%2.2%
30 Day-6.7%0.7%8.0%
90 Day15.7%2.6%-9.6%
1 Year55.9%55.9%21.8%18.1%-2.3%-3.9%
3 Year-25.2%-25.2%28.8%14.0%-7.6%-14.8%
5 Year98.6%98.6%30.4%7.9%-0.3%-12.9%

Price Volatility Vs. Market

How volatile is Theravance Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Theravance Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 0TB (€25) is trading below our estimate of fair value (€81.24)

Significantly Below Fair Value: 0TB is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 0TB is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: 0TB is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 0TB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 0TB has negative assets, so we can't compare its PB Ratio to the XE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Theravance Biopharma forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

48.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0TB is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 0TB is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 0TB is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 0TB's revenue (32.9% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 0TB's revenue (32.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 0TB's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Theravance Biopharma performed over the past 5 years?

-4.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 0TB is currently unprofitable.

Growing Profit Margin: 0TB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 0TB is unprofitable, and losses have increased over the past 5 years at a rate of -4.9% per year.

Accelerating Growth: Unable to compare 0TB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0TB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.2%).


Return on Equity

High ROE: 0TB's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Theravance Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: 0TB has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 0TB has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 0TB has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 0TB's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 0TB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 0TB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Theravance Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 0TB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 0TB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 0TB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 0TB's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 0TB's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Rick Winningham (59yo)

5.92yrs

Tenure

US$5,932,412

Compensation

Mr. Rick E. Winningham has been the Chairman and Chief Executive Officer at Theravance Biopharma, Inc. since its spin-off from Theravance, Inc. since July 2013 and since June 2014 respectively. Mr. Winning ...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD5.93M) is above average for companies of similar size in the German market ($USD1.50M).

Compensation vs Earnings: Rick's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Rick Winningham
Chairman & CEO5.92yrsUS$5.93m1.37% $21.8m
Andrew Hindman
Senior VP & CFO0.92yrUS$3.76m0.021% $325.2k
Bradford Shafer
Executive VP5.67yrsUS$2.47m0.11% $1.8m
Brett Haumann
Senior VP of Clinical Development & Chief Medical Officer5.42yrsUS$2.46m0.50% $7.9m
Frank Pasqualone
Senior VP & Chief Commercial Operations Officer4.17yrsUS$2.46m0.35% $5.5m
Vijay Sabesan
Senior Vice President of Technical Operations2.75yrsno data0.32% $5.1m
Gail Cohen
Vice President of Corporate Communications & Investor Relationsno datano datano data
Rhonda Farnum
Vice President of Sales & Marketing1.83yrsno datano data
Dennis Driver
Senior VP of Human Resources4.17yrsno datano data
Phillip Worboys
Senior Vice President of Research & Translational Science4.17yrsUS$2.40m0.56% $8.9m

4.2yrs

Average Tenure

49yo

Average Age

Experienced Management: 0TB's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rick Winningham
Chairman & CEO5.92yrsUS$5.93m1.37% $21.8m
William Young
Lead Independent Director6.08yrsUS$393.88k0.092% $1.5m
Eran Broshy
Independent Director5.92yrsUS$353.38k0.042% $658.2k
George Whitesides
Independent Director6.58yrsUS$337.88k0.38% $6.0m
Burton Malkiel
Independent Director6.58yrsUS$381.88k0.14% $2.2m
Robert Gunderson
Independent Director6.58yrsUS$337.88k0.069% $1.1m
Dean Mitchell
Independent Director5.92yrsUS$359.88k0.065% $1.0m
Donal O'Connor
Independent Director4.58yrsUS$359.88k0.054% $859.8k
Susan Molineaux
Independent Director5.08yrsUS$355.88k0.065% $1.0m
Laurie Smaldone Alsup
Independent Director2.25yrsUS$339.88k0.040% $627.9k

6.0yrs

Average Tenure

66yo

Average Age

Experienced Board: 0TB's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.4%.


Top Shareholders

Company Information

Theravance Biopharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theravance Biopharma, Inc.
  • Ticker: 0TB
  • Exchange: DB
  • Founded: 2013
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.727b
  • Listing Market Cap: US$1.586b
  • Shares outstanding: 63.09m
  • Website: https://www.theravance.com

Number of Employees


Location

  • Theravance Biopharma, Inc.
  • Ugland House
  • South Church Street
  • George Town
  • Grand Cayman
  • KY1-1104
  • Cayman Islands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TBPHNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDMay 2014
0TBDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2014

Biography

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease. Its product portfolio also include TD-1473, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn’s disease. In addition, the company’s product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY ELLIPTA for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Mylan Ireland Limited, Janssen Biotech, Inc., Alfasigma S.p.A, Trek Therapeutics, PBC, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/25 23:19
End of Day Share Price2020/05/25 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.